Clinicians who once prescribed these medications only for diabetes now explore their use for cardiovascular support, liver health, and even early cognitive protection
Multiple glucagon-like peptide-1 (GLP-1) agonist medications, created for the treatment of type 2 diabetes mellitus, are now labeled for the treatment of obesity
The results showed that the treatment with Ru(II)-OH reduced the tumor volume by 35%, the treatment with NP2 by 66%, and the treatment with NP4 by 91% (Fig
Deciding to stop Tirzepatide after meeting your weight loss goals requires careful consideration and expert advice
The most important consideration is that your choice is an informed one, based on science, personal routine, and realistic expectations
Dumn MJ, Patel K